Time filter

Source Type

WENZHOU, China, May 24, 2017 /PRNewswire/ -- Hebron Technology Co., Ltd. ("Hebron" or the "Company") (Nasdaq: HEBT), a developer, manufacturer and installer of valves and pipe fittings for use in the pharmaceutical, biological, food and beverage, and other clean industries, today announced it has won a bid on the design and implementation of an oil-free compressed air pipe project (the "Project") at a pharmaceutical production facility owned by Tianjin Chase Sun Pharmaceutical Co., Ltd. ("Chase Sun"), a top 100 pharmaceutical company in China by sales with over 6,000 employees and over RMB 3.9 billion in annual sales. Mr. Anyuan Sun, Chairman and Chief Executive Officer of Hebron, commented, "Our winning bid for the Project speaks to the quality of our valve and pipe products and the reputation of our technical team in providing holistic production line solutions for leading pharmaceutical companies in China. We are excited about the opportunity to participate in Chase Sun's expansion projects and look forward to growing this relationship. Kudos to our marketing and technical teams for their dedicated and diligent efforts to make this happen." About Tianjin Chase Sun Pharmaceutical Co., Ltd. Tianjin Chase Sun Pharmaceutical Co., Ltd. ("Chase Sun") (300026.SZ) is one of China's 100 leading pharmaceutical companies by sales. Founded in 1996 and Headquartered in Tianjin City, China, Chase Sun is a group of companies with over 6,000 employees and net sales of RMB 3.9 billion in 2016, focusing on researching, developing, manufacturing and marketing of traditional Chinese medicine ("TCM"), synthetic drugs, biotech drugs and medical devices. The Company's common stock has been traded on Shenzhen GEM under ticker 300026 since October 2009. More information about Chase Sun can be found at www.chasesun.cn. About Hebron Technology Co., Ltd. Established in January 2005 and headquartered in Wenzhou City, Zhejiang Province, China, Hebron Technology Co., Ltd. ("Hebron" or the "Company") engages in research, development, and manufacture of highly specialized valves and pipe fitting products for use in the pharmaceutical, biological, food and beverage, and other clean industries. The Company also offers its customers comprehensive pipeline design, installation, construction, and ongoing maintenance services as holistic solution services. This press release contains information about Hebron's view of its future expectations, plans and prospects that constitute forward-looking statements. Actual results may differ materially from historical results or those indicated by these forward-looking statements as a result of a variety of factors including, but not limited to, risks and uncertainties associated with its ability to raise additional funding, its ability to maintain and grow its business, variability of operating results, its ability to maintain and enhance its brand, its development and introduction of new products and services, the successful integration of acquired companies, technologies and assets into its portfolio of products and services, marketing and other business development initiatives, competition in the industry, general government regulation, economic conditions, dependence on key personnel, the ability to attract, hire and retain personnel who possess the technical skills and experience necessary to meet the requirements of its clients, and its ability to protect its intellectual property. Hebron encourages you to review other factors that may affect its future results in Hebron's registration statement and in its other filings with the Securities and Exchange Commission. For more information, please contact: To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/hebron-technology-co-ltd-wins-bid-for-a-project-at-leading-pharmaceutical-company-in-tianjin-300462890.html


About Tianjin Chase Sun Pharmaceutical Co., Ltd. Tianjin Chase Sun Pharmaceutical Co., Ltd. ("Chase Sun") (300026.SZ) is one of China's 100 leading pharmaceutical companies by sales. Founded in 1996 and Headquartered in Tianjin City, China, Chase Sun is a group of companies with over 6,000 employees and net sales of RMB 3.9 billion in 2016, focusing on researching, developing, manufacturing and marketing of traditional Chinese medicine ("TCM"), synthetic drugs, biotech drugs and medical devices. The Company's common stock has been traded on Shenzhen GEM under ticker 300026 since October 2009. More information about Chase Sun can be found at www.chasesun.cn. About Hebron Technology Co., Ltd. Established in January 2005 and headquartered in Wenzhou City, Zhejiang Province, China, Hebron Technology Co., Ltd. ("Hebron" or the "Company") engages in research, development, and manufacture of highly specialized valves and pipe fitting products for use in the pharmaceutical, biological, food and beverage, and other clean industries. The Company also offers its customers comprehensive pipeline design, installation, construction, and ongoing maintenance services as holistic solution services. This press release contains information about Hebron's view of its future expectations, plans and prospects that constitute forward-looking statements. Actual results may differ materially from historical results or those indicated by these forward-looking statements as a result of a variety of factors including, but not limited to, risks and uncertainties associated with its ability to raise additional funding, its ability to maintain and grow its business, variability of operating results, its ability to maintain and enhance its brand, its development and introduction of new products and services, the successful integration of acquired companies, technologies and assets into its portfolio of products and services, marketing and other business development initiatives, competition in the industry, general government regulation, economic conditions, dependence on key personnel, the ability to attract, hire and retain personnel who possess the technical skills and experience necessary to meet the requirements of its clients, and its ability to protect its intellectual property. Hebron encourages you to review other factors that may affect its future results in Hebron's registration statement and in its other filings with the Securities and Exchange Commission. For more information, please contact: To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/hebron-technology-co-ltd-wins-bid-for-a-project-at-leading-pharmaceutical-company-in-tianjin-300462890.html


Sun C.,Tianjin Chasesun Pharmaceutical Co. | Cao J.,Tianjin University of Science and Technology
Lecture Notes in Electrical Engineering | Year: 2014

Pyrrolizinone derivatives were discovered showing remarkable anti-inflammatory and analgesic activities. Based on the SAR summarized before, a series of pyrrolizinone derivatives were designed and synthesized in this paper. All the eight target compounds were characterized by 1HNMR spectra, and the test of anti-inflammatory and analgesic activities is in progress. © Springer-Verlag Berlin Heidelberg 2014.


Ding J.,Fudan University | Li Q.-Y.,Fudan University | Wang X.,Fudan University | Sun C.-H.,Tianjin Chasesun Pharmaceutical Co. | And 2 more authors.
Journal of Neurochemistry | Year: 2010

Rho kinase (ROCK) may play an important role in regulating biological events of cells, including proliferation, differentiation and survival/death. Blockade of ROCK promotes axonal regeneration and neuron survival in vivo and in vitro, thereby exhibiting potential clinical applications in spinal cord damage and stroke. Our previous studies have demonstrated that Fasudil, a selective ROCK inhibitor, induced neuroprotection in vitro. Here we used an in vivo model of hypoxia/reoxygenation (H/R) injury to examine the neuroprotective effect of Fasudil, and explore its possible mechanism(s) in vivo. H/R resulted in the loss of hippocampal neurons, accompanied by increased apoptosis of neurons in hippocampus. The expression of ROCK II and activity of ROCK in the brain were increased after H/R, and located only in microglia, but not in astrocytes and neurons. The administration of Fasudil inhibited the activity of ROCK in brain tissue and cultured microglia, and protected hippocampal neurons against H/R injury. Further immunohistochemical analysis and cytokine determination revealed that Fasudil inhibited inducible nitric oxide synthase immunoreactivity in microglia and pro-inflammatory factors in brain tissue after H/R, which is consistent with the observation wherein Fasudil reduced the pro-inflammatory factors nitric oxide, IL-1β, IL-6 and TNF-α, and increased anti-inflammatory factor IL-10 in cultured microglia under normoxic or hypoxic conditions. Our results indicate that inhibition of ROCK by Fasudil may represent a useful therapeutic perspective by inhibiting microglial inflammatory responses in the CNS. © 2010 International Society for Neurochemistry.


Ding J.,Huashan Hospital | Ding J.,Fudan University | Li Q.-Y.,Huashan Hospital | Yu J.-Z.,Shanxi Datong University | And 4 more authors.
Molecular and Cellular Neuroscience | Year: 2010

Rho kinase (ROCK) is important in fundamental processes of cell proliferation and survival. Blockade of ROCK promotes stem cell survival in vitro and axonal regeneration in vivo, exhibiting therapeutic potential such as spinal cord injuries and stroke. Here, we used the model of hypoxia/reoxygenation (H/R) injury to explore the possibility whether Fasudil, a ROCK inhibitor in clinical application for subarachnoid hemorrhage and stroke, mobilizes adult neural stem cells in vivo. Most interestingly, Fasudil triggers neurogenesis especially in the subventricular zone after H/R. The increase of Brdu+ cholinergic neurons was observed in striatum and forebrain cortex of Fasudil-treated mice after 30 days. Further observation demonstrates that both levels of granulocyte colony-stimulating factor (G-CSF) and astrocytes expressing G-CSF were elevated in mice treated with Fasudil, as compared to mice injected with saline. In vitro H/R model of cultured astrocytes, Fasudil promoted astrocytes to produce G-CSF in a dose-dependent manner. In addition, antibody neutralization and receptor blocking of the G-CSF pathway clearly demonstrate that Fasudil-induced neurogenesis was mediated partially through astrocyte-derived G-CSF. Our results indicate that Fasudil might represent a promising therapeutic perspective by mobilizating endogenous adult neural stem cells in the CNS. © 2009 Elsevier Inc. All rights reserved.


Ye H.,Nankai University | Liu R.,Nankai University | Li D.,Nankai University | Liu Y.,Nankai University | And 7 more authors.
Organic Letters | Year: 2013

A facile approach to the diazotransfer reagent of imidazole-1-sulfonyl azide was reported. The procedure was well optimized to clarify potential explosion risks. A high production yield as well as small batch variation was achieved even without careful pretreatment of reagents and solvents. HPLC and NMR methods to monitor the process were provided. These features made this protocol suitable for large scale preparation in academia and industry as well. © 2012 American Chemical Society.


Patent
Tianjin Chasesun Pharmaceutical Co. and Third Military Medical University | Date: 2011-03-21

The use of Kukoamine A and Kukoamine B in the preparation of drugs for the prevention and treatment of sepsis and autoimmune disease is disclosed. Bacterial endotoxin/lipopolysaccaride (LPS) and unmethylated DNA (CpG DNA) of bacteria, the major pathogen-associated molecular patterns in sepsis and autoimmune disease, are specifically targeted, while the disclosed use directionally isolates lead compounds from traditional Chinese medicine. These measures can overcome the major defects of uncertainty of pharmacological material basis and drug targets of extracts and constituents of traditional Chinese medicine. The disclosed use can help in developing a safe, effective and quality controllable drug for prevention and treatment of sepsis and autoimmune disease so as to help solve the present lack of effective drugs in clinical treatment.


Patent
Third Military Medical University and Tianjin Chasesun Pharmaceutical Co. | Date: 2013-09-18

Provided are salts of kukoamine B, their preparation method and their use in preventing and treating sepsis diseases.


Patent
Third Military Medical University and Tianjin Chasesun Pharmaceutical Co. | Date: 2013-05-15

Use of kukoamine A and kukoamine B in preparing medicine for preventing and treating sepsis and autoimmune diseases. The kukoamine A and kukoamine B are extracted from cortex lycii radicis. The medicine is used for antagonism of bacterial endotoxin (LPS) and bacteria non-methylated DNA (CpG DNA).


Patent
Tianjin Chasesun Pharmaceutical Co. | Date: 2011-03-21

Salts of kukoamine B, their preparation method and their pharmaceutical use in preparation of drugs for preventing and treating sepsis. Experiments indicate that salts of kukoamine B have a good effect on antagonizing the key factors inducing sepsis, and can be used in the preparation of drugs for preventing and treating sepsis. Under the current circumstances of the lack of effective measures for the treatment of sepsis in clinical practice, the medicinal formulations, which comprise the salts of kukoamine B, pharmaceutically acceptable carrier and/or diluent, provide a new approach for the prevention and treatment of sepsis.

Loading Tianjin Chase Sun Pharmaceutical Co. collaborators
Loading Tianjin Chase Sun Pharmaceutical Co. collaborators